Skip to content

Investigation of effects of Ritalin on giggle incontinence in children

Investigation of effects of Ritalin on giggle incontinence in children referring to Dr Sheikh hospital

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20111024007892N7
Enrollment
20
Registered
2017-12-29
Start date
2014-11-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urinary incontinence. Functional urinary incontinence

Interventions

Intervention 1: Intervention group: Patients are prescribed 0.2 milligram of Ritalin daily for one moth. It is recommended that the drug be given to children before going to school. Intervention 2: Co
Treatment - Drugs
Intervention group: Patients are prescribed 0.2 milligram of Ritalin daily for one moth. It is recommended that the drug be given to children before going to school
Control group: Patients will be given Oxybutynin drug with dose of 0.1 milligram per kilogram for one month.

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: older than five years old patients with giggle incontinence completion of informed consent form no existence of urological diseases

Exclusion criteria

Exclusion criteria: patients with neurogenic bladder congenital disorders of urinary system urinary tract obstruction neurological disorders such as myelomenoncule unwillingness to participate in the study

Design outcomes

Primary

MeasureTime frame
Rate of control and improvement of incontinence after use of Ritalin. Timepoint: A month after use of Ritalin. Method of measurement: Medical response is divided to 3 levels as following: 1-no response 2- relative response as reduction of incontinence numbers to half and 3- complete improvement.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnoosh Azarfar

Mashhad University of Medical Sciences

azarfara@mums.ac.ir+98 51 3726 9021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026